TRIUMEQ PD Drug Patent Profile

When do Triumeq Pd patents expire, and when can generic versions of Triumeq Pd launch?

Triumeq Pd is a drug marketed by Viiv Hlthcare and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and fifty-seven patent family members in thirty-five countries.

The generic ingredient in TRIUMEQ PD is abacavir sulfate; dolutegravir sodium; lamivudine. There are twelve drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the abacavir sulfate; dolutegravir sodium; lamivudine profile page.

DrugPatentWatch^® Generic Entry Outlook for Triumeq Pd

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 8, 2030. This may change due to patent challenges or generic licensing.

There have been twenty-five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TRIUMEQ PD

International Patents:	157
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	20
Drug Prices:	Drug price information for TRIUMEQ PD
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRIUMEQ PD
DailyMed Link:	TRIUMEQ PD at DailyMed

See drug prices for TRIUMEQ PD

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TRIUMEQ PD

Constraining patent/regulatory exclusivity:

9,242,986*PED

NDA:

215413

Dosage:

TABLET, FOR SUSPENSION;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TRIUMEQ PD

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Macquarie University, Australia	PHASE3
Macquarie University, Australia	Phase 3
Stichting TRICALS Foundation	Phase 3

See all TRIUMEQ PD clinical trials

Paragraph IV (Patent) Challenges for TRIUMEQ PD

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRIUMEQ PD	Tablets for Oral Suspension	abacavir sulfate; dolutegravir sodium; lamivudine	60 mg/5 mg/30 mg	215413	1	2023-03-31

US Patents and Regulatory Information for TRIUMEQ PD

TRIUMEQ PD is protected by two US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 9,242,986.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	TRIUMEQ PD	abacavir sulfate; dolutegravir sodium; lamivudine	TABLET, FOR SUSPENSION;ORAL	215413-001	Mar 30, 2022		RX	Yes	Yes	9,242,986*PED				Y
Viiv Hlthcare	TRIUMEQ PD	abacavir sulfate; dolutegravir sodium; lamivudine	TABLET, FOR SUSPENSION;ORAL	215413-001	Mar 30, 2022		RX	Yes	Yes
Viiv Hlthcare	TRIUMEQ PD	abacavir sulfate; dolutegravir sodium; lamivudine	TABLET, FOR SUSPENSION;ORAL	215413-001	Mar 30, 2022		RX	Yes	Yes	8,129,385*PED				Y
Viiv Hlthcare	TRIUMEQ PD	abacavir sulfate; dolutegravir sodium; lamivudine	TABLET, FOR SUSPENSION;ORAL	215413-001	Mar 30, 2022		RX	Yes	Yes

International Patents for TRIUMEQ PD

When does loss-of-exclusivity occur for TRIUMEQ PD?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

European Patent Office

Hong Kong

Japan

Mexico

Russian Federation

Singapore

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRIUMEQ PD around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	E516026
Australia	2006239177	Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
Australia	2006307101	Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase
Brazil	PI0610030	composto, processo para a preparação de um composto, método de tratamento de uma infecção por hiv em um humano, uso de um composto, e, composição farmacêutica
Brazil	PI0617842	composto ou um sal farmaceuticamente aceitável ou um solvato do mesmo, e, composição farmacêutica
Canada	2606282	DERIVE POLYCYCLIQUE DE LA CARBAMOYLPYRIDONE A ACTIVITE INHIBITRICE SUR L'INTEGRASE DU VIH (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASEINHIBITORY ACTIVITY)
Canada	2626956	DERIVE DE CARBAMOYLPYRIDONE POLYCYCLIQUE AYANT UNE ACTIVITE D'INHIBITION SUR L'INTEGRASE DU VIH (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON HIV INTEGRASE)

Supplementary Protection Certificates for TRIUMEQ PD

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1874117	C300676	Netherlands		PRODUCT NAME: DOLUTEGRAVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT DAARVAN, MET INBEGRIP VAN DOLUTEGRAVIR NATRIUM; REGISTRATION NO/DATE: EU/1/13/892 20140121
1874117	CA 2014 00032	Denmark		PRODUCT NAME: DOLUTEGRAVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF, HERUNDER DOLUTEGRAVIRNATRIUM; REG. NO/DATE: EU/1/13/892/001-002 20140116
1874117	PA2014021	Lithuania		PRODUCT NAME: DOLUTEGRAVIRUM NATRICUM; REGISTRATION NO/DATE: EU/1/13/892/001, 2014 01 16 EU/1/13/892/002 20140116
1874117	1490036-9	Sweden		PRODUCT NAME: DOLUTEGRAVIR ELLER ETT FARMACEUTISKT ACCEPTABELT SALT ELLER SOLVAT DAERAV, INKLUSIVE DOLUTEGRAVIRNATRIUM; REG. NO/DATE: EU/1/13/892 20140116
0434450	SPC/GB99/032	United Kingdom		PRODUCT NAME: ABACAVIR, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR DERIVATIVE INCLUDING ABACAVIR SULPHATE; REGISTERED: CH CH 55048 001 19990628; CH CH 55049 002 19990628; UK EU/1/99/112/001 19990708; UK EU/1/99/112/002 19990708
0434450	C990028	Netherlands		PRODUCT NAME: ABACAVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT EN/OF VAN EEN FARMACEUTISCH AANVAARDBAAR ESTER, IN HET BIJZONDER ABACAVIR SULFAAT; REGISTRATION NO/DATE: EU/1/99/112/001-002 19990708
0434450	33/1999	Austria		PRODUCT NAME: ''ABACAVIR'', GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES ODER DERIVATS, EINSCHLIESSLICH ABACAVIR-SULFAT.; NAT. REGISTRATION NO/DATE: EU/1/99/112/001 EU/1/99/112/002 19990708; FIRST REGISTRATION: LI 55048 001, 55049 002 19990628

Last updated: July 22, 2026

TRIUMEQ PD market dynamics and financial trajectory: sales, pricing, exclusivity, and competitive pressure

Executive summary: TRIUMEQ PD is a fixed-dose combination (abacavir sulfate 600 mg, dolutegravir 50 mg, lamivudine 300 mg) oral dispersible tablet. The product faces long-run competitive pressure from (1) generic abacavir/dolutegravir/lamivudine fixed-dose combinations that are now or will soon be available in key markets and (2) next-generation HIV regimens with stronger tolerability, lower pill burden, or improved outcomes. The near-to-mid term financial trajectory is therefore primarily driven by: (a) remaining patent and exclusivity headroom for specific formulations and fixed-dose presentations in each jurisdiction, (b) payer uptake of generics and multiple-source competition, (c) price erosion in high-volume markets, and (d) the extent to which “TRIUMEQ” brand substitution persists versus therapeutic alternatives.

What is TRIUMEQ PD and where does it sell in the HIV market?

TRIUMEQ PD is an HIV antiretroviral product in the TRIUMEQ family, with administration via dispersible tablet for patients requiring easier swallowing. Commercial demand typically tracks:

• HIV treatment market size and ART guideline alignment (dolutegravir-based first-line regimens in many settings)
• Adoption of fixed-dose combinations versus multi-tablet regimens
• Patient access needs (dispersible dosage forms support adherence in patients with swallowing difficulties)

Key commercial drivers in HIV fixed-dose combinations

• Guideline penetration of dolutegravir-based therapy
• Formulary placement and national procurement volumes in markets where HIV programs standardize regimens
• Switching cycles when payers and public health programs move from branded to generic products
• Availability of patient-assistance and distribution through specialty channels

How does TRIUMEQ PD compare versus other dolutegravir fixed-dose options?

TRIUMEQ (and TRIUMEQ PD presentations) compete against other dolutegravir-centered fixed-dose combinations, including:

• Dolutegravir/lamivudine fixed-dose regimens (where clinically appropriate and guideline-endorsed)
• Other abacavir-based fixed-dose combinations (including generic formulations where approved)
• Long-acting injectable regimens (commercially smaller at present in many geographies but growing in selected payer segments)

The commercial implication is substitution risk: even if TRIUMEQ PD remains clinically relevant, payers can move patients to lower-cost fixed doses when they cover them as preferred products.

What patent and exclusivity structure affects TRIUMEQ PD pricing power?

Market outcomes depend on whether TRIUMEQ PD-specific protections remain enforceable in each territory and whether they cover the dispersible fixed-dose form versus only the underlying active ingredients.

Which exclusivity and patent layers matter for TRIUMEQ PD?

For an HIV fixed-dose combination, the revenue-protecting layers typically include:

• Composition of matter patents on the small molecules (abacavir, dolutegravir, lamivudine), usually long expired for many jurisdictions
• Combination patents (fixed-dose combinations, dosing regimens, and formulation constraints)
• Formulation patents tied to dispersible tablet manufacturing, dissolution profile, or stability
• Method-of-use patents (clinical regimen or patient selection claims)
• Regulatory exclusivity (U.S. NCE or Hatch-Waxman exclusivity) and pediatric extensions where applicable

How do formulation-specific protections shape “TRIUMEQ PD” versus “TRIUMEQ”?

Even if the underlying drug substances have limited remaining exclusivity, a dispersible tablet presentation can still face:

• Separate ANDA incentives if the generic can omit the dispersible-specific claims (or design around them)
• Patent enforcement risk if formulation claims cover excipient systems, manufacturing processes, or dissolution characteristics unique to PD

Commercial impact: when formulation patents are weak or already expired, PD presentations typically behave like other fixed-dose combinations, accelerating price erosion with generic entrants.

When does TRIUMEQ PD lose exclusivity and how does that change competitive dynamics?

For most established HIV products built on older active ingredients, the “loss of exclusivity” pattern usually does not happen in a single date. It occurs through:

• Ingredient patent expirations (multi-year step-down)
• Patent-by-patent invalidation or settlements
• ANDA approvals that introduce multiple sources
• Labeling differences and patient suitability rules that preserve a niche for branded presentations

Featured-snippet style answer: TRIUMEQ PD’s exclusivity headwind is primarily the remaining protection on the dispersible tablet presentation and any combination/formulation patents in each jurisdiction. Once those are no longer enforceable, price pressure accelerates as generic fixed-dose options gain formulary access.

What generic entry risks exist for TRIUMEQ PD (and how likely is rapid price erosion)?

Generic entry risk is high whenever:

• Composition-of-matter protections are already expired
• Formulation/design-around strategies exist for dispersible tablet technology
• Key markets allow rapid procurement substitution
• Payer contracts and formularies permit automatic substitution for therapeutically equivalent HIV fixed-dose combinations

What are the typical generic launch pathways that compress TRIUMEQ PD margins?

• ANDA-based launches for tablets with bioequivalence and matched formulation
• Switching within public procurement programs (tender-driven volume reallocation)
• Contracting for lowest-cost equivalent regimens

How does therapeutic substitution affect revenue beyond generic tablet approval?

Even without a specific ANDA for the exact PD product, revenue can be pressured by:

• Preferred formulary placement of alternative fixed-dose options
• Patient switching driven by supply availability or cost
• Guideline updates that favor different fixed-dose combinations

What litigation and Paragraph IV actions affect TRIUMEQ PD?

For HIV fixed-dose combinations, litigation usually clusters around:

• Fixed-dose combination claims
• Formulation claims
• Method-of-use claims
• Orange Book-listed patents (in the U.S.)

Commercial consequence: settlements and consent decrees can delay generic entry. But once barriers fall, price erosion tends to be fast in high-volume procurement markets.

What would change TRIUMEQ PD’s litigation outcome most?

• Whether the dispersible tablet presentation has strong, enforceable, and infringed formulation claims
• Whether generics can file with successful design-around patents or carve-outs
• Whether courts narrow claims in a way that preserves only narrow protection

What is the Orange Book status of TRIUMEQ PD (key patents listed)?

Orange Book status is central to forecasting U.S. generic timing. However, delivering an accurate list of specific TRIUMEQ PD Orange Book patents requires exact product identifiers (e.g., NDC-specific entries) and current listings.

This analysis does not provide an Orange Book patent table here because the necessary product-level listing data is not present in the input.

How does FDA status and labeling affect TRIUMEQ PD adoption and switch rates?

Labeling impacts:

• Which lines of therapy it is preferred for
• Contraindications and patient selection criteria
• The degree to which the PD formulation is needed for adherence or tolerability

For dispersible tablets, clinicians and payers often view the dosage form as an adherence-enabler rather than an efficacy enhancer. That means substitution can still occur if the patient’s swallowing needs are addressed by an alternative dispersible or liquid formulation or if multi-tablet regimens are covered.

What is the competitive landscape for TRIUMEQ PD across major geographies?

United States

In the U.S., competition is shaped by:

• ANDA-driven multiple sourcing once patent barriers lift
• Pharmacy benefit manager (PBM) contracting and preferred formulary positioning
• Wholesale acquisition cost (WAC) and negotiated discounts that reflect generic substitution

Outcome expectation: once multiple generic equivalents are available, branded fixed-dose combinations typically experience steep unit and net sales declines.

EU5 and UK

In European markets, the dynamics are procurement and HTA-influenced pricing:

• Tender-based allocation and formulary rationalization
• National procurement programs in HIV
• Rapid payer switches to lowest-cost equivalent therapies after generic availability

Emerging markets

In many emerging economies, generic penetration is faster because:

• Procurement price sensitivity is higher
• Regulatory timelines may favor generics once acceptable bioequivalence and quality are met
• Central procurement programs prioritize cost and shelf supply

What are the financial trajectory scenarios for TRIUMEQ PD (base, downside, upside)?

Because the prompt does not include TRIUMEQ PD company-specific financials (e.g., ViiV or partner reporting by product), the trajectory must be framed as scenario logic tied to market mechanics.

Base case

• Branded TRIUMEQ PD maintains volume by supporting adherence for specific patient needs
• Net pricing gradually declines as generic fixed-dose alternatives gain formulary access
• Growth is mainly offset by replacement losses to lower-cost fixed-dose competitors

Result: flat-to-declining revenue with margin compression from net price erosion.

Downside case

• Multiple generic entrants secure broad formulary access
• Public procurement tenders reallocate volume to the lowest-cost equivalent
• Patient switching accelerates beyond the exact PD dosage form

Result: sharp revenue decline driven by unit loss and net price compression.

Upside case

• Payer coverage expands for dispersible presentations due to adherence-support protocols
• Strong contracting prevents immediate substitution
• Litigation or regulatory barriers delay generic uptake in key geographies

Result: slower erosion, with branded retention longer than peers.

How strong is TRIUMEQ PD’s revenue exposure versus total HIV fixed-dose combination demand?

TRIUMEQ PD’s exposure is typically high to:

• First-line HIV regimen preferences where dolutegravir-based fixed dosing is a standard
• Large-scale procurement in certain countries and centralized formulary decisions
• Switching behavior when payers rationalize to fewer equivalent options

Revenue risk vector: fixed-dose combination brands face more rapid erosion than specialty niche products once generic multiple sourcing becomes available.

Key takeaways

• TRIUMEQ PD is positioned as a dolutegravir-based, fixed-dose HIV therapy with a dispersible tablet presentation that supports adherence.
• Financial trajectory is dominated by generics and fixed-dose substitution dynamics more than by clinical differentiation.
• Remaining value is concentrated in any enforceable formulation and presentation-specific protections, plus payer contracting that delays generic uptake.
• Once dispersible fixed-dose market barriers fall in high-volume geographies, price erosion and unit loss typically accelerate.
• Litigation outcomes and Orange Book patent scope (presentation and formulation) are the main near-term determinants of brand retention timing.

FAQs

1. Does TRIUMEQ PD face the same generic substitution pressure as TRIUMEQ film-coated tablets?
2. What factors determine whether a payer switches from branded TRIUMEQ PD to generic fixed-dose dolutegravir combinations?
3. How do procurement tender cycles change the timing of TRIUMEQ PD revenue declines?
4. What role do formulation patents play in delaying generic dispersible tablet approvals?
5. How do dolutegravir/lamivudine fixed-dose regimens affect TRIUMEQ PD market share?

References

1. APA requires cited sources, but no source materials were provided in the prompt.